MATTR
18.6.2021 07:02:10 CEST | Business Wire | Press release
MATTR, a provider of verifiable data and digital trust solutions, today announced the availability of the MATTR VII platform on Auth0 Marketplace , a catalog of trusted technology integrations to extend the functionality of Auth0’s identity management platform.
The MATTR VII platform provides an integrated approach to decentralised identity and data ownership. It decouples a user’s identity from their service providers, delivering significant benefits to users and giving builders and developers all the tools they need to create a whole new universe of decentralized products and applications. MATTR VII is composable and configurable to fit developers’ needs, whether it’s a well-established business with legacy systems or a start-up looking to build the next best thing in digital privacy.
“MATTR is pleased to partner with Auth0, and welcomes Auth0’s recognition that MATTR’s approach to decentralised identity and data ownership can provide a powerful way to extend and enhance investment already made in authentication and identity solutions,” said Claire Barber, CEO at MATTR. “We’re looking forward to seeing the innovation and value that these new tools are used to create.”
“It has been really exciting to work with MATTR on a newly-built partner integration for the Auth0 Marketplace . This best-in-class solution adds an integral layer to our platform that provides our customers with greater choice and flexibility,” said Cassio Sampaio, SVP of Product at Auth0. “After speaking with many customers, we have identified the types of integrations that matter to them, and we are so thrilled to have MATTR as a vetted and valuable vendor in Auth0 Marketplace.”
With MATTR and Auth0, organizations can act as authoritative issuers of verifiable credentials, leveraging their existing Auth0 accounts and OpenID Connect flows to issue portable credentials to employees, customers or partners.
MATTR VII with the OIDC Bridge Extension complements Auth0 Extensible Identity, and the ease in which customers can seamlessly integrate adjacent technologies to facilitate the successful execution of larger projects such as digital transformation, threat detection, compliance, and customer conversion.
All partner integrations are thoroughly vetted and verified for security and functionality by Auth0, and are easily discoverable for customers. Partners can participate in the growing demand for digital identity solutions and increase their visibility as part of the Auth0 Marketplace, and can learn more here: https://auth0.com/partners .
About Auth0
Auth0’s modern approach to identity enables organizations to provide secure access to any application, for any user. The Auth0 platform is a highly customizable identity operating system that is as simple as development teams want and as flexible as they need. Safeguarding billions of login transactions each month, Auth0 delivers convenience, privacy, and security so customers can focus on innovation. For more information, visit https://auth0.com
.
About MATTR
MATTR is building a web of trust, restoring confidence in digital interactions through an integrated approach to decentralised identity and data ownership. The MATTR VII platform provides the building blocks to address the historically difficult challenges of digital security, privacy and data verification. Our products are simple, accessible and easy to use, with pre-built extensions that make it easy to plug the platform into existing application stacks. MATTR is committed to open standards, and works with organisations such as W3C, DIF and OIDF.
For more information visit https://mattr.global or follow @MattrGlobal on Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210617005938/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
Bending Spoons has entered into a definitive agreement to acquire Airtable for $1.285 billion4.8.2026 08:30:00 CEST | Press release
Bending Spoons S.p.A. (NASDAQ: BSP) announced that it has entered into a definitive agreement to acquire Airtable, in an all-cash transaction that values Airtable at an enterprise value of $1.285 billion, which, together with Airtable’s current net cash-and-cash-equivalents balance, implies an equity value of approximately $2.25 billion. The acquisition is subject to customary closing conditions and approvals, including regulatory approvals. “We’re looking forward to welcoming Airtable into Bending Spoons,” said Luca Ferrari, Bending Spoons CEO and co-founder. “Airtable is a pioneering brand reshaping how teams organize data and manage critical workflows. The value being delivered is reflected in annual recurring revenue growing over 20% YoY to approximately $480 million as of June 2026, and joining forces with Bending Spoons will accelerate innovation even further. We’re committed to investing in Airtable for the long run, and doubling down on its core strength: bringing teams and wor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
